KEYTRUDA 25 mg/mL concentrate for solution for infusion, CETUXIMAB, olomorasib
LOXO-RAS-20001
Phase 2 small_molecule active
Quick answer
KEYTRUDA 25 mg/mL concentrate for solution for infusion, CETUXIMAB, olomorasib for KRAS G12C-Mutant Advanced Solid Tumors is a Phase 2 program (small_molecule) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly Co.
- Indication
- KRAS G12C-Mutant Advanced Solid Tumors
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active